This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Mebicar
- DrugBank Accession Number
- DB13522
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Mebicar (DB13522)
- Weight
- Average: 198.226
Monoisotopic: 198.111675707 - Chemical Formula
- C8H14N4O2
- Synonyms
- Tetramethylglycoluril
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Mebicar. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Mebicar. Acetophenazine The risk or severity of CNS depression can be increased when Acetophenazine is combined with Mebicar. Agomelatine The risk or severity of CNS depression can be increased when Agomelatine is combined with Mebicar. Alfentanil The risk or severity of CNS depression can be increased when Alfentanil is combined with Mebicar. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as imidazolidinones. These are organic compounds containing an imidazolidinone moiety, which is an imidazolidine ring bearing a ketone.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Azolidines
- Sub Class
- Imidazolidines
- Direct Parent
- Imidazolidinones
- Alternative Parents
- Ureas / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Aliphatic heteropolycyclic compound / Azacycle / Carbonic acid derivative / Carbonyl group / Hydrocarbon derivative / Imidazolidinone / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound
- Molecular Framework
- Aliphatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 55FE6NPG89
- CAS number
- 10095-06-4
- InChI Key
- XIUUSFJTJXFNGH-OLQVQODUSA-N
- InChI
- InChI=1S/C8H14N4O2/c1-9-5-6(11(3)7(9)13)12(4)8(14)10(5)2/h5-6H,1-4H3/t5-,6+
- IUPAC Name
- (3as,6as)-1,3,4,6-tetramethyl-octahydro-[1,3]diazolo[4,5-d]imidazole-2,5-dione
- SMILES
- CN1[C@H]2[C@@H](N(C)C1=O)N(C)C(=O)N2C
References
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 244.0 mg/mL ALOGPS logP -0.74 ALOGPS logP -0.8 Chemaxon logS 0.09 ALOGPS pKa (Strongest Basic) -2.7 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 47.1 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 49.03 m3·mol-1 Chemaxon Polarizability 19.84 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-03di-2900000000-0c8bf10b2fd705c21c5a Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0002-0900000000-b2bf0436a32b3f777b23 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0002-0900000000-12fcdd84b8fc4fa8fbd6 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0005-0900000000-e7f789b45de4fa123f41 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-0900000000-d3dd1e7579e365bace5a Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4l-6900000000-0cda837fa458e02a9fd9 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-01ox-0900000000-a2a3475e7d1073825677 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 140.71002 predictedDeepCCS 1.0 (2019) [M+H]+ 143.10558 predictedDeepCCS 1.0 (2019) [M+Na]+ 149.48645 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:43 / Updated at June 12, 2020 16:53